Prognosis and Clinical Characteristics of Inflammatory Breast Cancer_West China Medical Journal

Authors：

 ZhanRuiyu ,  YanXi , LiaoZhengyin , ZhengHong

Oncology Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

YanXi, Email: 852143552@qq.com

Keywords：

Inflammatory breast cancer; Clinicopathological characteristics; Univariate; Multivariate; Survival analysis

DOI：

10.7507/1002-0179.20160012

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the prognostic factors for inflammatory breast cancer based on the data from West China Hospital with a relatively large sample. Methods Clinical data of 41 patients with histopathologically confirmed inflammatory breast cancer (IBC) who received treatment at West China Hospital Oncology Center of Sichuan University between January 2009 and December 2014 were collected and analyzed. Log-rank test and Cox regression model were used for statistical analysis. Results In the study, negative estrogen receptor, negative progestrone receptor and positive human epidermal growth factor receptor-2 were identified in 58.5%, 61.0% and 34.2% of the inflammatory breast cancer tissues, respectively. Progress free survival (PFS) were between 2 and 60 months, with a median of 35 months. Univariate analysis showed that Tumor Node Metastasis (TNM) stage (P=0.016) and therapeutic effect (P=0.002) influenced the survival. Multivariate analysis showed that TNM stage (P=0.006), therapeutic effect (P=0.002), and anthracycline-taxane based chemotherapy (P=0.041) were the significant prognostic factors. Conclusion TNM stage is the major prognostic factor for IBC. Preoperative chemotherapy with paclitaxel-epirubicin combination can improve the PFS of IBC. Comprehensive treatment mode with operation is recommended for the treatment of IBC.

Citation： ZhanRuiyu, YanXi, LiaoZhengyin, ZhengHong. Prognosis and Clinical Characteristics of Inflammatory Breast Cancer. West China Medical Journal, 2016, 31(1): 48-52. doi: 10.7507/1002-0179.20160012 Copy

1.	Lee BJ, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital[J]. Surg Gynecol Obstet, 1924, 39:580-595.
2.	Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival:the surveillance, epidemiology, and end results program at the National Cancer Institute[J]. J Natl Cancer Inst, 2005, 97(13):966-975.
3.	Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer:consensus statement for standardized diagnosis and treatment[J]. Ann Oncol, 2011, 22(3):515-523.
4.	Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer:PET/CT, MRI, mammography, and sonography findings[J]. Breast Cancer Res Treat, 2008, 109(3):417-426.
5.	Van Der Auwera I, Van Laere SJ, Van Den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification[J]. Clin Cancer Res, 2004, 10(23):7965-7971.
6.	Boussen H, Cristofanilli M, Zaks T, et al. Phase Ⅱ study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer[J]. J Clin Oncol, 2010,28(20):3248-3255.
7.	Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer[J]. Clin Cancer Res, 2004, 10(18 Pt 1):6215-6221.
8.	Dawood S, Broglio K, Gong Y, et al. Prognostic significance of HER-2 status in women with inflammatory breast cancer[J]. Cancer, 2008, 112(9):1905-1911.
9.	Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence:understanding the biology of a unique disease[J]. Cancer, 2007, 110(7):1436-1444.
10.	Parton M, Dowsett M, Ashley S, et al. High incidence of HER-2 positivity in inflammatory breast cancer[J]. Breast, 2004, 13(2): 97-103.
11.	Zell JA, Tsang WY, Taylor TH, et al. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC):analysis of 2,014 IBC patient cases from the California Cancer Registry[J]. Breast Cancer Res, 2009, 11(1):R9.
12.	Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer:a population-based survival analysis[J]. J Clin Oncol, 2005, 23(9):1941-1950.
13.	Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2):474-484.
14.	Nogi H, Kobayashi T, Tabei I, et al. The predictive value of PgR and HER-2 for response to primary systemic chemotherapy in inflammatory breast cancer[J]. Int J Clin Oncol, 2008, 13(4): 340-344.
15.	Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer:the M. D. Anderson Cancer Center experience[J]. Clin Breast Cancer, 2004, 4(6):415-419.
16.	Kim T, Lau J, Erban J. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes:a systematic review[J]. Clin Breast Cancer, 2006, 7(5): 386-395.

1. Lee BJ, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital[J]. Surg Gynecol Obstet, 1924, 39:580-595.
2. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival:the surveillance, epidemiology, and end results program at the National Cancer Institute[J]. J Natl Cancer Inst, 2005, 97(13):966-975.
3. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer:consensus statement for standardized diagnosis and treatment[J]. Ann Oncol, 2011, 22(3):515-523.
4. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer:PET/CT, MRI, mammography, and sonography findings[J]. Breast Cancer Res Treat, 2008, 109(3):417-426.
5. Van Der Auwera I, Van Laere SJ, Van Den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification[J]. Clin Cancer Res, 2004, 10(23):7965-7971.
6. Boussen H, Cristofanilli M, Zaks T, et al. Phase Ⅱ study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer[J]. J Clin Oncol, 2010,28(20):3248-3255.
7. Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer[J]. Clin Cancer Res, 2004, 10(18 Pt 1):6215-6221.
8. Dawood S, Broglio K, Gong Y, et al. Prognostic significance of HER-2 status in women with inflammatory breast cancer[J]. Cancer, 2008, 112(9):1905-1911.
9. Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence:understanding the biology of a unique disease[J]. Cancer, 2007, 110(7):1436-1444.
10. Parton M, Dowsett M, Ashley S, et al. High incidence of HER-2 positivity in inflammatory breast cancer[J]. Breast, 2004, 13(2): 97-103.
11. Zell JA, Tsang WY, Taylor TH, et al. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC):analysis of 2,014 IBC patient cases from the California Cancer Registry[J]. Breast Cancer Res, 2009, 11(1):R9.
12. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer:a population-based survival analysis[J]. J Clin Oncol, 2005, 23(9):1941-1950.
13. Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2):474-484.
14. Nogi H, Kobayashi T, Tabei I, et al. The predictive value of PgR and HER-2 for response to primary systemic chemotherapy in inflammatory breast cancer[J]. Int J Clin Oncol, 2008, 13(4): 340-344.
15. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer:the M. D. Anderson Cancer Center experience[J]. Clin Breast Cancer, 2004, 4(6):415-419.
16. Kim T, Lau J, Erban J. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes:a systematic review[J]. Clin Breast Cancer, 2006, 7(5): 386-395.

West China Medical Journal

Prognosis and Clinical Characteristics of Inflammatory Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content